We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Omeros Corp (OMER) NPV

Sell:$2.63 Buy:$3.29 Change: $0.09 (3.38%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Change: $0.09 (3.38%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Change: $0.09 (3.38%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Its lead lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome, and COVID-19. OMS906, its inhibitor of MASP-3, an activator of the alternative pathway of complement, is initiating a Phase I b clinical program in paroxysmal nocturnal hemoglobinuria (PNH).

Contact details

201 Elliott Ave W
United States
+1 (206) 6765000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$166.86 million
Shares in issue:
62.73 million
United States
US dollar

Key personnel

  • Gregory Demopulos
    Chairman of the Board, President, Chief Executive Officer
  • Michael Jacobsen
    Vice President - Finance, Chief Accounting Officer, Treasurer
  • George Gaitanaris
    Vice President - Science, Chief Scientific Officer
  • Peter Cancelmo
    Vice President, General Counsel, Secretary
  • Peter Williams
    Vice President - Human Resources
  • Christopher Bral
    Vice President - Non Clinical Development
  • Nadia Dac
    Vice President, Chief Commercial Officer
  • Bruce Meiklejohn
    Vice President - Chemistry, Manufacturing and Controls
  • Catherine Melfi
    Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
  • Tina Quinton
    Vice President - Patents

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.